<DOC>
	<DOCNO>NCT03101579</DOCNO>
	<brief_summary>It prove intrathecal chemotherapy main treatment strategy leptomeningeal metastasis . At present , commonly use drug intrathecal chemotherapy include methotrexate , cytarabine , liposomal cytarabine . In recent decade , new effective drug discover intrathecal chemotherapy . The recurrence leptomeningeal metastases inevitable even aggressive treatment . There effective treatment recurrent leptomeningeal metastasis comprehensive treatment include intrathecal methotrexate and/or cytarabine , central nervous system radiation therapy , systemic chemotherapy well tyrosine-kinase inhibitor drug . The quality life extremely poor , patient always die short time . Pemetrexed newer multitargeted antifolate show activity various tumor . It high effectiveness safety , use first-line treatment non-small cell lung cancer . In animal study , pemetrexed demonstrate suppress tumor growth completely mice two type transplant human colon xenograft resistant methotrexate . Therefore , purpose study evaluate safety feasibility intrathecal pemetrexed patient recurrent leptomeningeal metastasis non-small cell lung cancer .</brief_summary>
	<brief_title>Intrathecal Pemetrexed Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This single arm clinical trial . The objective study patient recurrent leptomeningeal metastasis non-small cell lung cancer comprehensive treatment . 10-15mg pemetrexed administrate intrathecal injection , plus dexamethasone 5 mg , twice per week 2 week , follow per week 2-4 week .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients diagnose leptomeningeal metastasis nonsmall cell lung cancer receive comprehensive treatment , include intrathecal methotrexate and/or cytarabine , central nervous system radiation therapy , systemic chemotherapy well tyrosinekinase inhibitor drug . 2 . Patients diagnose recurrent leptomeningeal metastasis positive cerebrospinal fluid cytological examination persist aggravate symptom 1 week , increase intracranial pressure ( ＞300 mmH2O ) . 3 . No severe abnormal liver kidney function ; WBC≥2500/mm3 , Plt≥60000/mm3 ; 4 . No severe chronic disease ; 5 . No severe dyscrasia . 6 . Signed informed consent form . 1 . Patients clinical manifestation nervous system failure include severe encephalopathy , grade IIIIV white matter lesion confirm image examination , moderate severe coma , glasgow coma score le 9 point ; 2 . Patients severe nervous system injury relate treatment , chemical meningitis ; 3 . Patients accept systemic chemotherapy within two week , new molecular target therapeutic drug le one month ; 4 . Patients poor compliance , reason , researcher consider unsuitable participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leptomeningeal metastasis</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Intrathecal chemotherapy</keyword>
	<keyword>Pemetrexed</keyword>
</DOC>